ICYMI, some of this week’s featured content includes video interviews about ellacor for wrinkles and diversity and wellness in dermatology. Plus, stories on new FDA approvals, advances in the AD pipeline, our top hair loss articles, and more.
This week’s edition of The Mainstream Patient features stories about gua sha facial massages, kojic acid for hyperpigmentation, fragrance in skin care, plus more.
In this first part of our coverage of “The Skin of Color Update Pre-Conference Virtual Symposium” held August 3, we review challenging cases of melasma, vitiligo, and post-inflammatory hyperpigmentation in skin of color patients.
Shino Bay Aguilera, DO, reflects on his keynote address highlighting diversity and wellness in aesthetic medicine at Aesthetics Biomedical’s “Perspectives: The Evolution of Aesthetics” symposium.
Researchers from UT Southwestern Medical Center have investigated a new way to use AI to determine the metastatic potential of melanoma.
The FDA has accepted the New Drug Application (NDA) for tapinarof as a treatment for plaque psoriasis in adults and set the PDUFA target action date to Q2 2022.
UCB announced that more than 90% of patients treated with bimekizumab have maintained IGA 1/0 results in their long-term BE BRIGHT trial.
The International Psoriasis Council (IPC)’s new binary classification system aims to streamline access to systemic treatments for patients who previously were likely undertreated.
More research is needed to understand the pathogenesis underlying this association.
Roy Geronemus, MD, clinical professor of dermatology at New York University Medical Center & Dermatology Times editorial advisory board member, discusses the recent FDA clearance of ellacor Micro-Coring Technology for treatment of moderate to severe wrinkles in the mid to lower face.
The FDA has granted priority review to Merck’s application for pembrolizumab, a treatment for melanoma.
In honor of National Hair Loss Awareness Month, Nutrafol pledges to donate a portion of its’ total revenue in the month of August to the National Alopecia Areata Foundation.
Vector-borne infectious diseases are spreading and skin cancer is rising because of climate change.
Do COVID-19 antigens cause hypersensitivity to dermal fillers?
A recent statement by Regeneron noted that chronic spontaneous urticaria is the fifth disease associated with positive phase 3 results involving the monoclonal antibody.
In light of National Hair Loss Awareness month, we’ve aggregated our top 10 hair loss articles of 2021 so far.
A phase 2 clinical trial on remetinostat for the treatment of BCC in adult patients has been published in the Clinical Cancer Research journal and shows promising results.
diversity GlobalData has published a report that predicts the atopic dermatitis pipeline will see great transformation and growth in the next 10 years.